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Available online xxxxBackground: Impaired renal function predicts mortality in acute coronary syndrome (ACS), but its evolution im-
mediately following index ACS and preceding next ACS has not been described in detail. We aimed to describe
this evolution using serial measurements of creatinine, glomerular ﬁltration rate [eGFRCr] and cystatin C [CysC].
Methods: From 844 ACS patients included in the BIOMArCS study, we analysed patient-speciﬁc longitudinal
marker trajectories from the case-cohort of 187 patients to determine the risk of the endpoint (cardiovascular
death or hospitalization for recurrent non-fatal ACS) during 1-year follow-up. Study included only patients
with eGFRCr ≥ 30 ml/min/1.73 m2. Survival analyses were adjusted for GRACE risk score and based on data
N30 days after the index ACS (mean of 8 sample per patient).
Results:Mean age was 63 years, 79% were men, 43% had STEMI, and 67% were in eGFR stages 2–3. During hospi-
talization for index ACS (median [IQR] duration: 5 (3–7) days), CysC levels indicated deterioration of renal func-
tion earlier than creatinine did (CysC peaked on day 3, versus day 6 for creatinine), and both stabilized after two
weeks. Higher CysC levels, but not creatinine, predicted the endpoint independently of the GRACE score within
the ﬁrst year after index ACS (adjusted HR [95% CI] per 1SD increase: 1.68 [1.03–2.74]).
Conclusion: Immediately following index ACS, plasma CysC levels deteriorate earlier than creatinine-based indi-
ces do, but neither marker stabilizes during hospitalization but on average two weeks after ACS. Serially mea-
sured CysC levels predict mortality or recurrence of ACS during 1-year follow-up independently of patients'
GRACE risk score.
© 2019 Elsevier B.V. All rights reserved.Keywords:
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Renal dysfunction, including mild renal impairment (eGFR 60–89
ml/min/1.73 m2) [1,2], is strongly associated both with short- and
long-termmortality in patients with ST elevation myocardial infarction
(STEMI) and in those with non-STEMI [3–5]. Patients with chronic kid-
ney disease (CKD) are often treated less aggressively for acute coronarylution of renal function and predictive value of serial renal assessments
.org/10.1016/j.ijcard.2019.07.052
2 M. Brankovic et al. / International Journal of Cardiology xxx (xxxx) xxxsyndrome (ACS) than those without CKD [3,4,6]. However, even if they
are on optimal therapy they will still have poorer prognosis [7]. Renal
dysfunction is associated with coronary atherosclerosis, including
higher coronary plaque burden, plaques containing greater necrotic
core and more dense calcium, as well as with abnormalities of cardiac
muscle, including left ventricular hypertrophy, dilated cardiomyopathy,
and systolic dysfunction [8–10]. Several studies have shown that spe-
ciﬁc comorbidities such as hypertension, diabetes, and dyslipidemia,
contribute both to cardiovascular and renal damage [11,12]. Neuro-
hormonal activation is also affected after ACS [13–15], and angiotensin
IImay inﬂuence deterioration of both cardiovascular and renal function-
ing [13,16,17].
In heart failure (HF), renal dysfunction has been identiﬁed as the
most prevalent comorbidity and strongly predicted adverse clinical out-
comes [18,19]. Worsening renal function has also been used as the pri-
mary endpoint in several clinical trials in acute HF [20,21].Underlying
hemodynamic dependence between the heart and kidneys including
renal perfusion hemodynamics and systemic neuro-hormonal activa-
tion, has been identiﬁed as the main driver of such a relationship [22].
In spite of these overlapping pathophysiological aspects between
the heart and kidneys, the detailed temporal evolution of renal function
immediately following index ACS, and preceding a recurrent ACS, has
not yet been described. Existing studies have mostly assessed renal
function only at a single time point to investigate its prognostic value,
and have used for example time of admission, a moment during in-
hospital stay or time of discharge as ‘study baseline’. However, it is un-
clear whether a patient's renal function examined at these time points
during hospitalization reﬂects “true” renal functioning or whether it is
temporarily disturbed by the index ACS. Moreover, it remains unknown
at which moment after ACS renal function stabilizes. Knowing these
temporal patterns may help us in expanding our understanding of
renal dysfunction in patients with ACS, and thereby aid in identifying
high-risk subgroups.
The aim of our study was two-fold: (1) to describe the evolution of
renal function from its initial change during ACS until stabilization, ac-
cording to the kinetics of several renal function parameters (plasma cre-
atinine, estimated glomerular ﬁltration rate [eGFRCr], and cystatin C
[CysC]), (2) to investigate the predictive value of serial renal marker as-
sessments within the ﬁrst year after index ACS. For the latter purpose,
we also examined whether rates of change of these renal markers are
relevant for clinical risk prediction in ACS.2. Methods
2.1. BIOMArCS
BIOMArCS is a multi-centre prospective study conducted in 18 Dutch hospitals [23].
Details on the BIOMArCS design are reported elsewhere [24]. Brieﬂy, we included patients
whowere hospitalized for ACS including STEMI, non-STEMI, and unstable angina pectoris
(UAP), with ≥1 cardiovascular risk factor (Table S1); eGFRCr b 30 ml/min/1.73 m2 was an
exclusion criterion because of the potential inﬂuence of renal clearance on certain bio-
markers investigated in the BIOMArCS cohort [24]. All patients were treated according
to prevailing guidelines and at the discretion of the treating physician. The study protocol
has been approved by the Institutional Review Board of all participating hospitals and
written informed consent was obtained from all patients.2.2. Selection of patients to analyse the relation between renal markers and repeat ACS
For the analysis of the relation between (renal) biomarkers and repeat ACS during 1-
year follow-up, we applied a case-cohort design, which allowed a comparison of all study
endpoint cases to a limited random sample of non-cases (instead of all non-cases), thereby
increasing the study's efﬁciency [25]. For this purpose, after study completion
(i.e., inclusion, follow-up, and study endpoint adjudication) a sub-cohort of 150 patients
was randomly sampled from the parent cohort (n = 844), using a computer generated
random sampling procedure. Subsequently, all patients who experienced the endpoint,
but who were not a part of the random sub-cohort were added (37 cases), so that the
case-cohort comprised 187 patients (Fig. 1). Thus, we analysed all cases, but analysed
only those non-cases (non-endpoint patients) who were present in the random sub-
cohort.Please cite this article as:M. Brankovic, I. Kardys, V. van den Berg, et al., Evo
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ACS
To enable a precise description of early washout biomarker patterns, a total of 68 (8%)
BIOMArCS patients underwent additional blood sampling at 24, 48, 72 and 96 h after the
index ACS. We excluded the 6 patients who experienced the study endpoint within the
ﬁrst two month due to potential inﬂuence on stabilization of the washout pattern, and
enriched with the endpoint-free patients from the random sub-cohort. Thus, a total of
185 patients were available for the analysis of washout patterns of renal biomarkers
(Fig. 1).
2.4. Follow-up visits and blood sample collection
Blood samples were collected at admission, hospital discharge, and every two weeks
after index ACS during the ﬁrst six months, followed by monthly collection until one year
(Fig. 1). A visitwindowof±1weekwas allowed, and amaximumof two consecutive visits
were allowed to be skipped (for personal reasons). If logistic reasons hindered inclusion
during hospitalization, patients could be included on the ﬁrst outpatient visit within six
weeks after discharge; the sampling schedulewas then adapted accordingly. A trained re-
search nurse interviewed the patients at each visit and obtained data on anginal status
(Canadian Cardiovascular Society classiﬁcation), HF symptomatology (New York Heart
Association classiﬁcation), and factors thatmight inﬂuence biomarker levels, e.g. smoking,
occurrence of infections, inﬂammatory or allergic responses, alterations inmedication, in-
terventional or operative procedures and hospital admission. Blood samples were proc-
essed on-site and transported batch-wise under controlled conditions to the department
of Clinical Chemistry of the ErasmusMC, Rotterdamwhere theywere stored until analysis
was performed.
Glomerular ﬁltration rate (GFR) was determined by the Modiﬁcation of Diet in Renal
Disease (MDRD) Study equation [26]. Patients were categorized using the modiﬁed eGFR
deﬁnition from the National Kidney Foundation – Kidney Disease Outcome Quality Initia-
tive (K/DOQI) clinical practice guidelines [27].
2.5. Analysis of renal markers
In the 187 case-cohort patients and in the 185 patients that comprise the washout
analysis set, renal biomarkers (creatinine and CysC)weremeasured batch-wise at the lab-
oratory of the department of Clinical Chemistry and Hematology of the UniversityMedical
Center Utrecht. Creatinine was measured on clinical routine equipment (AU5800,
Beckman Coulter, Brea, CA, USA). Cystatin C was measured by ELISA following manufac-
turer's instructions (mouse-anti human DuoSet DY1196, R&D Systems, Oxon, UK; inter-
and intra-assay CV b10%). The EDTA-plasmawas used for biomarker analysis. Importantly,
laboratory personnel were blinded to any patient data and scope of the study, whereas
biomarker measurements did not interfere with treatment.
2.6. Study endpoints
The study endpoint was a composite of cardiac mortality or a diagnosis of a non-fatal
myocardial infarction or unplanned coronary revascularization due to progressive angina
pectoris during 1-year follow-up. Any death was considered cardiac unless documented
otherwise. Incident non-fatalmyocardial infarctionwasdeﬁned as the combination of typ-
ical ischemic chest complaints and objective evidence of myocardial ischemia or myocar-
dial necrosis as demonstrated by the ECG and/or elevated cardiac markers. The criteria for
non-fatal myocardial infarction during follow-up were the same as those for the index
event (Table S1, points 1 and 2 of the inclusion criteria). A Clinical Event Committee,
blinded for the renal biomarker results, reviewed hospital records and discharge letters
and adjudicated the study endpoints.
3. Statistical analysis
3.1. Case-cohort – prediction of events
Categorical baseline data are summarized by percentages, and con-
tinuous data by medians and 25th–75th percentiles. Differences be-
tween cases and non-cases were evaluated by classical statistical tests,
as speciﬁed in the caption of Table 1.
To obtain valid inferences for the relation between the temporal
evolvement of a biomarker and the incidence of the study endpoint, the
longitudinal- and event-processes must be jointly modelled [28]. We ap-
plied Bayesian semiparametric joint models for this purpose, which com-
bine linear regression and Cox proportional hazard regression. Linear
mixed-effects (LME)models were used to describe patient-speciﬁc longi-
tudinal biomarker trajectories B(t) as a function of time (t). Non-linear
trajectories were modelled by cubic splines. 2Log-transformations of bio-
marker values were used to assure normal distributions of regression re-
siduals. More speciﬁcally, the unit of analysis was the Z-score (i.e. the
standardized form) of the 2log-biomarker, which allows a directlution of renal function and predictive value of serial renal assessments
i.org/10.1016/j.ijcard.2019.07.052
Fig. 1. Participants ﬂow chart, study design, and sampling schema. Legend: Case-Cohort was constructed from a random sample of 150 patients from the full cohort (n=844, all enrolled
patients) and enrichedwith all cases (n=37). For the case-cohort, blood sampleswere collected at admission, at hospital discharge, and subsequently every twoweeks during theﬁrst six
months, followed bymonthly collection until 1 year (sampling for prediction). Risk assessment time intervalswere: (1)Main analysis N30 days until study endpoint or last samplemoment,
(2) Sensitivity analysis N7 days until study endpoint or last sample moment. Washout sub-cohort was constructed from a random sample of 68 patients from the parent cohort in whom
additional samples were collectedwithin 24, 48, 72 and 96 h after admission, at the day of hospital discharge, and at 2, 4 and 8 weeks (washout sampling). Patients who experienced new
events within the ﬁrst 60 days form the index ACSwere excluded due to potential inﬂuence on stabilization of the washout pattern (n=6). The washout samplewas then enriched with
123 patients who did not experience incident events from the sub-cohort of 150 random patients, resulting in a total of 185 patients for the washout sub-cohort.
3M. Brankovic et al. / International Journal of Cardiology xxx (xxxx) xxxcomparison of the effects of separate markers. Results are presented as
hazard ratios (HR) and corresponding 95% conﬁdence intervals (CI) for
a 1SD difference of the biomarker on the log-scale.
The LMEmodels not only provide unbiased estimates B(t) of the bio-
marker level at timepoint t, but also of its instantaneous rate of change
(or: slope) B′(t) at t, that corresponds to the ﬁrst derivative of B(t). Since
we also aimed to study rate of change, we also provided HRs for the in-
stantaneous slope of the marker's trajectory. Further details on this
method of dynamic prediction modeling were described elsewhere
[29]. Results are presented as HRs (95% CIs) for a 0.1 SD difference of
the marker's rate of change on the log-scale.
Analyses were ﬁrst performed univariably, and subsequently multi-
variable adjustment was performed. For this purpose, the GRACE riskPlease cite this article as:M. Brankovic, I. Kardys, V. van den Berg, et al., Evo
among patients with acu..., International Journal of Cardiology, https://doiscore for assessment of post-discharge death andmyocardial infraction,
as recommended by international guidelines [30–32], was used. This
speciﬁc GRACE risk model consists of age, ﬁrst troponin (or CKMB)
after discharge, history ofMI, congestiveHF andwhether CABGwasper-
formed at the index hospitalization [33]. The survival model was ad-
justed for the GRACE risk score, and the LME model was adjusted for
GRACE risk score, sex, diabetes, history of coronary artery bypass sur-
gery, history of valvular heart disease, history of stroke, history of pe-
ripheral arterial disease.
To describe the average evolution of renal function during the year
preceding death or the recurrence of ACS, we analysed all available
data N30 days after the index ACS until the endpoint or last sample
moment.lution of renal function and predictive value of serial renal assessments
.org/10.1016/j.ijcard.2019.07.052
Table 1
Baseline characteristics of the parent cohort and case-cohort set.
Characteristics All
patients
Case-cohort
Non-cases Cases p-Value
Number of patients 844 142 45
Presentation and initial
treatment
Age, years, median (IQR) 62.5 (54.3,
70.2)
62.6
(55.0–70.9)
67.4
(57.1–76.5)
0.07
Male sex, % 77.9 78.2 80.0 0.79
Admission diagnosis, % 0.46
STEMI 51.7 45.8 35.6
NSTEMI 37.7 39.4 48.9
UAP 10.6 14.8 15.6
Culprit artery, %
RCA 33.1 34.5 26.7 0.33
LM 2.5 3.5 2.2 1.00
LAD 31.9 33.8 31.1 0.74
LCX 16.5 12.0 20.0 0.17
CAG performed, % 94.4 93.7 89.0 0.33
PCI performed, % 86.3 82.6 87.2 0.49
CKmax, U/L median (IQR) 513
(200-1370)
449
(190-1197)
389
(194-1122)
0.78
Killip class, % 0.012
Class I 94 82
Class II 4 16
Class III 2 0
Class IV 0 2
Renal function on admission
Urea, mmol/L median (IQR) 5.9
(5.0–7.0)
6.8
(4.7–7.9)
0.19
Creatinine, μmol/l median
(IQR)
82 (69–95) 87 (73–93) 0.22
eGFR, ml/min/1.73 m2
median (IQR)
83 (69–98) 78 (71–92) 0.21
KDOQI classiﬁcation, (%)
eGFR ≥90 ml/min/1.73 m2 35 24 0.16
eGFR 60–89 ml/min/1.73 m2 55 60
eGFR 30–59 ml/min/1.73 m2 10 16
Medical history, %
Diabetes mellitus 23.5 16.9 37.8 0.003
Hypertension 55.5 54.2 48.9 0.53
Dyslipidemia 49.3 50.7 44.4 0.46
Prior PCI 26.2 27.0 31.1 0.59
Prior CABG 10.0 8.5 24.4 0.004
Prior MI 26.9 30.3 31.1 0.92
Heart failure 2.4 2.8 8.9 0.097
Valvular heart disease 2.2 1.4 8.9 0.031
Prior CVA/TIA 9.0 11.3 20.0 0.13
PAD 8.9 6.3 22.2 0.004
Medication at ﬁrst blood
sampling moment from 7
days after index ACS, %
Aspirin 95.1 93.0 100 0.20
P2Y12 inhibitor 94.8 90.4 96.8 0.46
Vitamin K antagonist 6.9 7.9 9.7 0.72
Statins 95.8 95.6 96.8 1.00
Beta-blocker 90.1 85.1 93.5 0.37
ACE inhibitor or ARB 83.6 84.2 90.3 0.57
ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker; CABG: coro-
nary artery bypass grafting; CKmax:maximumcreatine kinase during the index admission;
LAD: left anterior descending artery; LCX: left circumﬂex artery; LM: left main coronary
artery; NSTEMI: non-ST-elevation myocardial infarction; PCI: percutaneous coronary in-
tervention; RCA: right coronary artery; STEMI: ST-elevation myocardial infarction; SD:
standard deviation; Troponinmax: maximum troponin value during the index admission;
UAP: unstable angina pectoris.
4 M. Brankovic et al. / International Journal of Cardiology xxx (xxxx) xxxTo investigate the predictive value of repeatedly measured markers,
we analysed all available data N30 days after the index ACS event, to en-
sure that all biomarkers were then stabilized. Additionally, a sensitivity
analysis was performed on all repeatedmeasurements N7 days after the
index ACS. Measurements that were obtained within 7 days after index
ACS were excluded to avoid biased estimates due to elevated bio-
markers induced by the index ACS.Please cite this article as:M. Brankovic, I. Kardys, V. van den Berg, et al., Evo
among patients with acu..., International Journal of Cardiology, https://do3.2. Analysis of evolution of renal function during the washout phase (im-
mediately following index ACS)
LME models were applied to investigate at which time point the
renal markers reach their highest point (creatinine, CysC) or lowest
point (eGFRCr) and at which time point they return to stable levels. All
renal biomarkers were 2log transformed, and non-linear evolutions
(for the ﬁxed- and random-effects parts) were modelled by restricted
cubic splines. We optimized the position of the spline knots by using
Akaike information criteria and Bayesian Information criteria. After
obtaining optimal evolution curves representing the washout patterns
of the renal markers, we calculated the maximum or minimum of
these curves to determine the time point of the peak or nadir. To deter-
mine the moment of marker stabilization, we also numerically com-
pared the deltas of biomarkers between every two consecutive blood
samples (a difference b1% signiﬁed a stabilization).
R statistical software (version 2.15.0)was used for advanced statisti-
cal analyses, in particular the package JMbayes [14]. All statistical tests
were two-tailed and p-values b0.05 were considered statistically
signiﬁcant.4. Results
4.1. Study endpoints and baseline characteristics
Of 844 enrolled patients, 45 reached the study endpoint during a
median (IQR) follow-up of 11.5 (2.7–12.1) months. Baseline character-
istics of all patients in the BIOMArCS study and in the case-cohort set are
shown in Table 1. In the case-cohort, on admissionmean (±SD) agewas
63 (±11) years, 79% were men, 43% had STEMI, 42% had non-STEMI,
and 15% had UAP. The median (IQR) eGFRCr was 81 (70–98) ml/min/
1.73 m2, and 33% of patients were in eGFR stage 1 (GFR ≥ 90), 56% in
stage 2 (GFR 60–89), and 11% in stage 3 (GFR 30–59).4.2. Average evolution of renal markers immediately following index ACS
A total of 687 samples were drawn from the 185 non-endpoint pa-
tients that comprise the washout analysis set, with a mean of 4 samples
per patient. Average washout evolutions of plasma creatinine, eGFRCr
and CysC are shown in left panel of Fig. 2. The ﬁgure shows that CysC
levels reached a peak on the 3rd day after index ACS. This was followed
by a nadir of eGFRCr on the 4th day, and a peak of creatinine levels on the
6th day.We also found different time intervals from the highest or low-
est point to stabilization for thesemarkers: CysC – 11days (stabilized on
day 13), eGFRCr – 10 days (stabilized on day 13) and creatinine – 8 days
(stabilized on day 14). Nevertheless, the stabilization of the markers
after index ACS appeared to be temporary.4.3. Average evolution of renal markers during the year preceding death or
next ACS
In the time-period N30 days after index ACS, a total of 1117 blood
samples were collected from 158 of the 185 patients that comprise
the case-cohort, with amedian of 7 samples per patient - the remain-
ing 27 patients (17 study endpoint cases) only had samples in the 0–
30 day time window. Although plasma creatinine levels increased
slightly prior to the incident event in patients who ultimately
reached the study endpoint, substantial overlap was present be-
tween average evolutions of these patients and those who remained
endpoint-free (Fig. 2: right panel). eGFRCr displayed similar dynam-
ics, but with a smaller overlap. Notably, plasma CysC showed sub-
stantially higher levels during follow-up in patients ultimately
reaching the study endpoint.lution of renal function and predictive value of serial renal assessments
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next ACS
Higher levels of CysC assessed at any point in time during follow-up
were positively associated with the endpoint (HR [95% CI]: per 1SD in-
crease of 2logCysC: 1.79 [1.21–2.63], p = 0.006). After controlling for
the GRACE risk score, CysC level remained a signiﬁcant predictor (ad-
justed HR [95% CI]: 1.63 [1.01–2.66], p= 0.043).
In the sensitivity analysis, CysC level measured serially N7 days after
the index ACS was slightly weaker, but also a signiﬁcant predictor (1.68
[1.13–2.46], p= 0.009). After adjustment for the GRACE risk score, the
risk estimates remained materially the same (adjusted HR [95% CI]:
1.63 [1.01–2.57], p= 0.045) (Table S2).
No clear associations were found between serially assessed plasma
creatinine or eGFRCr and the study endpoints (Table 2).
None of the slopes of the renal markers trajectories were associated
with the endpoint (Table 2, and Table S2).Fig. 2. Average evolution of renal markers immediately following index ACS and during the ye
follow-up time (days) starting from admission is displayed on the x-axis. Renal marker leve
hospital with corresponding interquartile range (dashed red lines). The left black dashed line
of eGFR, and the right black dashed line displays the time moments of biomarker stabilizatio
from the peaks/nadirs to stabilization. Right panel: the solid red line depicts the average ev
depicts the evolutions in endpoint-free patients. The dashed lines represent the 95% conﬁden
C (μg/ml); (For interpretation of the references to colour in this ﬁgure legend, the reader is ref
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In this prospective multicenter study, we sought to describe the lon-
gitudinal trajectories of different renal markers, and their impact on 1-
year cardiac outcome in patients with ACS. We found that plasma
CysC levels predict mortality or recurrence of ACS within the ﬁrst year
independently of patients' GRACE risk score. We also found that CysC
levels deteriorate earlier than creatinine-based indices do during
index ACS. Importantly, we observed that both renal markers usually
do not stabilize during hospitalization, but on average two weeks after
index ACS. Altogether, these ﬁndings underscore the relation of renal
dynamics with ACS, and carry implications for the monitoring of renal
function in these patients.
The majority of studies in patients with ACS have focused on prog-
nostic value of creatinine levels or eGFR assessed at one point in time.
However, the prognostic value of serial renal assessments, including
CysC levels, is less clear and has mainly been investigated in patientsar preceding death or recurrence of ACS or last sample moment. Legend: Left panel: the
ls are displayed on the y-axis. The solid red line depicts the median discharge day from
displays time of the highest peak of plasma creatinine and cystatin C and the lowest peak
n. The light blue area (between the two black dashed lines) represents the time period
olutions of renal markers in patients who reached the endpoint, and the solid blue line
ce interval. A. plasma creatinine (mmol/L); B. eGFR (ml/min/1.73 m2); C. plasma cystatin
erred to the web version of this article.)
lution of renal function and predictive value of serial renal assessments
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Table 2
Hazard ratios for the primary endpoint in relation to serially assessed marker levels N30 days after index ACS.
Geometric meane Levelsa Instantaneous slopeb
Mean− 1 SD Mean Mean + 1 SD HR (95% CI) p-Value HR (95% CI) p-Value
Creatinine 67 84 105
Crude model 1.28 (0.84–1.97) 0.28 1.00 (0.53–1.85) 0.98
+GRACE risk scorec,d 1.12 (0.73–1.76) 0.61 1.00 (0.53–1.89) 0.99
eGFR 64 88 120
Crude model 1.52 (0.97–2.37) 0.06 1.00 (0.53–1.86) 1.00
+ GRACE risk scorec,d 1.32 (0.85–2.10) 0.20 1.02 (0.56–1.87) 0.93
CysC 473.1 613.1 794.6
Crude model 1.79 (1.21–2.63) 0.006 0.99 (0.53–1.90) 0.98
+GRACE risk scorec,d 1.63 (1.01–2.66) 0.043 0.99 (0.53–1.83) 0.99
a Hazard ratios (HRs) and 95% conﬁdence interval (CI) are given per 1-SD increase (creatinine and cystatin C), and 1-SD decrease (eGFR) on the 2-log scale at any time point after
30 days after index ACS.
b HRs (95%) CI are given per 0.1-SD increase in the slope (creatinine and cystatin C), and 0.1-SD decrease (eGFR) on the 2-log scale at any time point after 30 days after index ACS.
c Longitudinal model adjusted for GRACE risk score, sex, diabetes, history of coronary artery bypass surgery, history of valvular heart disease, history of stroke, history of peripheral
arterial disease.
d Survival model adjusted for GRACE risk score. GRACE risk score is calculated as theweighted sum of age, ﬁrst troponin after discharge, history ofMI, congestive HF andwhether CABG
was performed at the index hospitalization.
e Geometric mean ± 1 standard deviation (SD) of the patient-speciﬁc biomarker values after 30 days (presented on the linear scale).
6 M. Brankovic et al. / International Journal of Cardiology xxx (xxxx) xxxwith HF [19,34]. In acute HF, studies have shown that worsening renal
function during hospitalization entails poor prognosis especially if a
patient's clinical status deteriorates simultaneously [35]. Otherwise,
small to moderate renal function decline during hospitalization in the
setting of aggressive diuresis may simply be result of decongestion
and clinically benign [36,37]. In chronic HF, serial measurements of cre-
atinine and CysC during outpatient follow-up strongly predicted long-
term adverse clinical outcomes such as HF rehospitalization and death
[34].
In patients with ACS, some authors [38] have speculated that assess-
ment of renal function should be repeated after hospital discharge to en-
sure that ‘true’ renal functioning is detected, and not transient renal
ﬂuctuations. However, no study has examined the evolution of renal
function during the washout phase early after ACS and during 1-year
follow-up. It is here that our study further extends existing evidence.
Our ﬁndings suggest incremental value of CysC levels for risk assess-
ment by means of the GRACE score. These ﬁndings are also supported
by Correa et al. [39], who found that CysC levels predicted cardiovascu-
lar death or HF hospitalization in patients after ACS, independently of
established cardiovascular risk predictors including troponins and
brain natriuretic peptide. Interestingly, Correa et al. collected samples
at a median of 14 days after ACS. This underpins ﬁndings from our
washout cohort, indicating that CysC level usually stabilizes on average
two weeks after ACS. Taken together, it seems reasonable to re-assess
CysC levels in the time period after hospital discharge in patients for
whom a more complete risk assessment is required.
Previous studies that also used repeated CysC measurements are
scarce. Akerblom et al. assessed whether repeatedly measured CysC
levels (at baseline, discharge, and the mean value of both measure-
ments) carry predictive value in 4295 patients with ACS and similar
baseline creatinine levels as those in our study [40]. They reported
that serial CysC assessment did not improve risk prediction. However,
our results were obtained using a different approach. Contrary to
Akerblom et al., we examined long-term temporal evolution of renal
markers, speciﬁcally by using repeated measurements up to 1 year
after hospital discharge to estimate the CysC trajectories in each patient.
We then jointly modelled these renal trajectories with time-to-event
analysis. This joint modeling approach carries several advantages. It en-
abled us to investigate the association with adverse events in a less bi-
ased way [41]. It also allowed us to examine the associations between
the rates of change of different renal function parameters and adverse
events. The latter analyses suggested that although CysC levels contrib-
ute to a patient's clinical risk, their rates of change do not. This is sup-
ported by Shlipak et al. who also could not demonstrate a signiﬁcant
association between change in creatinine (delta-creatininePlease cite this article as:M. Brankovic, I. Kardys, V. van den Berg, et al., Evo
among patients with acu..., International Journal of Cardiology, https://do≥0.3 mg/dl) and outcomes in patients with stable coronary artery dis-
ease (CAD) in the Heart and Estrogen/Progestin Replacement Study
(HERS) [42]. Thus, it appears that rate of change of renal function is
only relevant for clinical risk in patients with CAD and systolic dysfunc-
tion, or with HF [19,34,38].
Although we observed a slight deterioration of creatinine-based es-
timates prior to the incident endpoint, we could not conﬁrm their pre-
dictive value as found previously [1,2]. This may be explained by the
relatively low prevalence of patients with more severe renal dysfunc-
tion in our study. In fact, only 11% of our patients had moderate renal
impairment (eGFRCr 59–30ml/min/1.73m2) and therewere nopatients
with eGFRCr b 30 ml/min/1.73 m2 due to the exclusion criteria. How-
ever, it appears that CysC levels were still able to detect these subtle dif-
ferences, which may be of particular interest for patients with mild
eGFRCr reduction (eGFRCr 60–89 ml/min/1.73 m2), as was the case in
56% of patients included in the study. Indeed, studies have shown that
CysC levels correlate more closely with the true GFR than serum creati-
nine levels [43–45]. Although a possible non-renal link between CysC
and cardiovascular risk has been suggested [46], a recent Mendelian
randomization study by Van der Laan et al. could not substantiate a
causal role of CysC in etiology of cardiovascular disease [47]. Finally, al-
though such mild renal dysfunction usually does not require speciﬁc
management, accurate monitoring of these subtle differences by CysC
may carry potential for improving risk stratiﬁcation of these patients.
5.1. Study limitations
Several aspects of our study warrant consideration. First, the MDRD
equation, although validated in patientswith ACS, has limitations due to
the non-renal factors that inﬂuence creatininemeasures. Likewise, pro-
teinuriawas notmeasured in this cohort. Nevertheless, we choseMDRD
because it is themost widely utilized eGFRCr equation, and thus enables
comparisons with existing studies. Second, patients were excluded in
case of eGFRCr b 30 ml/min/1.73 m2, which limits generalizability of
our results to the ACS population at large. Yet we were able to demon-
strate, even in this ACS population with a lesser degree of renal impair-
ment, that renal dysfunction quantiﬁed by plasma CysC is associated
with cardiovascular events. Third, despite controlling analyses for
GRACE risk score, a risk model recommended in international guide-
lines, residual confounding may still be present.
6. Conclusion
Immediately following index ACS, plasma CysC levels deteriorate
earlier than creatinine-based indices do, but neither marker stabilizeslution of renal function and predictive value of serial renal assessments
i.org/10.1016/j.ijcard.2019.07.052
7M. Brankovic et al. / International Journal of Cardiology xxx (xxxx) xxxduring hospitalization but on average two weeks after ACS. Serially
measured CysC levels predict mortality or recurrence of ACS within
the ﬁrst year independently of GRACE risk score.
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